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European LeukemiaNet recommendations for the management
and avoidance of adverse events of treatment in chronic
myeloid leukaemia
JL Steegmann1, M Baccarani2, M Breccia3, LF Casado4, V García-Gutiérrez5, A Hochhaus6, D-W Kim7, TD Kim8, HJ Khoury9, P Le Coutre8,
J Mayer10, D Milojkovic11, K Porkka12,13, D Rea14, G Rosti2, S Saussele15, R Hehlmann16 and RE Clark17
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efﬁcacy, particularly
on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and
manageable, but they are increasingly important as therapy is potentially lifelong and multiple TKIs are available. For this reason,
the European LeukemiaNet panel for CML management recommendations presents an exhaustive and critical summary of AEs
emerging during CML treatment, to assist their understanding, management and prevention. There are ﬁve major conclusions.
First, the main purpose of CML treatment is the antileukemic effect. Suboptimal management of AEs must not compromise this
ﬁrst objective. Second, most patients will have AEs, usually early, mostly mild to moderate, and which will resolve spontaneously
or are easily controlled by simple means. Third, reduction or interruption of treatment must only be done if optimal management
of the AE cannot be accomplished in other ways, and frequent monitoring is needed to detect resolution of the AE as early as
possible. Fourth, attention must be given to comorbidities and drug interactions, and to new events unrelated to TKIs that are
inevitable during such a prolonged treatment. Fifth, some TKI-related AEs have emerged which were not predicted or detected
in earlier studies, maybe because of suboptimal attention to or absence from the preclinical data. Overall, imatinib has
demonstrated a good long-term safety proﬁle, though recent ﬁndings suggest underestimation of symptom severity by
physicians. Second and third generation TKIs have shown higher response rates, but have been associated with unexpected
problems, some of which could be irreversible. We hope these recommendations will help to minimise adverse events, and we
believe that an optimal management of them will be rewarded by better TKI compliance and thus better CML outcomes,
together with better quality of life.
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INTRODUCTION
Although successful pharmacologic treatment of chronic myeloid
leukaemia (CML) is nowadays likely to result in near-normal life
expectancy, at least a quarter of patients will change TKI at least
once during their life, because of either inadequate response or
intolerance.1–11 The clinical imperative for continuous daily
treatment over many years is burdened by the accompanying
long-standing adverse effects (AEs) and a resultant decreased
quality of life. The attention given by the scientiﬁc community to
AEs has grown over recent years, but our understanding remains
poor. We have no knowledge of why only some (and not all)
patients develop particular AEs, and this might be related to
many factors, including polymorphisms in genes that affect TKI
movement and metabolism.12 More generally, publications about
prevention and management of TKI AEs are scarce. Although this
problem has been addressed by the Council of Europe several
years ago,13 the dissemination and implementation of these
recommendations has been suboptimal.14
In view of these considerations, the European LeukemiaNet
working party on CML asked authors JLS and REC to convene a
panel of members who had previously published and/or expressed
an interest in AEs. Panel members were asked to review available
data in their ﬁeld of interest and to make recommendations for
when certain TKI should be optimally used or avoided. The present
publication represents a consensus document from email corre-
spondence and a series of meetings held during 2014 and 2015.
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General considerations and limitations of these recommendations
In CML, we have a somewhat simpler landscape than for many
other diseases, partly because of the fastidiousness devoted to
AEs in TKI studies and the several resultant publications.15–18 This
could be ascribed to regulatory issues, more commitment from
the pharmaceutical industry, and growing interest from the
haematologist and other health providers. However, current
recommendations have several limitations. The most important
is the scarcity of evidence for managing speciﬁc complications. In
addition, the ease of monitoring some laboratory parameters (for
example, blood counts or biochemical alterations in liver or renal
function), and if abnormal the protocolised requirement to stop/
change TKI therapy, could have underestimated the true
magnitude of some TKI-related AEs. In contrast, the difﬁculty of
monitoring other systems (for example, endothelium, the nervous
system) may account for the severity of some AEs, especially if
presenting after many years of TKI treatment. Finally, long-term
information on AEs is more available on imatinib than on other
TKIs regarding type, frequency, time of onset and severity of AEs.
Long-term observations on AEs exist only for imatinib, and we
have learned that a delayed presentation could be possible for
any AE.7
The prevention of AEs of TKI treatment of CML has been
addressed only marginally in randomized trials. Two reasons
account for this: ﬁrst, because it is not the objective of these kind
of trials, and second, because in pivotal randomized trials, the
spectrum of AEs is still being discovered and with longer follow-
up, unforeseen late AEs are revealed. Also, this topic cannot be
properly addressed in retrospective studies. The information on
the kinetics of appearance of AEs is scarce. Development of AEs
can be determined by type of TKI, dosage, schedule, disease
phase, concomitant medications and body size.
Our present recommendations comprise three types of
information. First, the kinetics of appearance of AEs, in order to
inform the reader when to be more cautious. Second, the
conditions before or concurrent with TKI treatment that predis-
pose to TKI toxicity. Here it is important to note that, while it is
sensible to treat comorbidities optimally (for example, the control
of hyperlipidemia) or to change food or lifestyle, there are only
very scarce data on whether this mitigates the incidence or
severity of AEs. Third, the hypotheses on pathogenesis that the
authors have offered in their studies. In the absence of evidence
for prevention of AEs, our recommendations are based on the
application of ars medica, reﬂecting the opinion given by the
authors of system-speciﬁc sections and the opinion of the panel
reviewers and members.
General approach to the management of AEs
Early and prompt recognition is crucial for optimal management,
without unduly compromising treatment continuity. First of all,
patient education on potential AEs and their time course is vital,
together with pre-emptive treatment to reduce AE risk (for
example, loperamide to pre-empt bosutinib-associated diarrhoea).
Most of the study protocols have used the National Cancer
Institute common toxicity criteria (NCI-CTC) for classifying the
severity of AEs, and there are similarities in management
strategies across different studies.1,2,5,19–23 It is worth noting that
the NCI-CTC criteria are not always precise enough to quantitate
the severity of AEs.
However, the success of these strategies has not been studied
in depth. Aspects such as reversibility, frequency of relapses and
severity are known only for a limited number of AEs. Our general
approach for managing AEs is summarised as follows, depending
on the grade of severity:
Grade 1 AE. No change in TKI therapy or dose is needed, though
the AE may require speciﬁc treatment.
Grade 2 AE. Withholding the TKI until the grade falls to o2 is
the preferred approach. However, it may be reasonable to initially
continue the TKI for a week with appropriate treatment of the AE
where practical, and then if there is no resolution, to withhold the
TKI until toxicity grade is o2, with weekly monitoring. In the case
of two or three episodes, we recommend dose reduction to the
next lower level.
Grade 3 AE. Withholding the TKI until the grade falls to o3 is
the recommended approach, and then resuming at the next lower
level. Another reasonable option is to withhold the drug until
severity falls to o2, and resume at the same dose. If there is no
resolution within 4 weeks, then discontinue the TKI, and switch to
another when appropriate. In the case of a third episode of grade
3, discontinuation and switching is the best option.
Grade 4 AE. Stop the TKI and switch to another TKI when
appropriate. A cautionary comment is pertinent here. In all studies
of TKIs, particularly in company-sponsored registration studies,
toxicity was sometimes reported to be ‘manageable’, meaning
that balancing dose interruption, dose reduction and some
symptomatic treatment, it was possible to keep most patients
on treatment with that TKI. The term ‘manageable’ has sense
when it is not possible for some reason to switch to another TKI.
But in all other cases the concept of ‘manageable’ should be
revised, and the pros and cons of continuing the same TKI, with
dose interruption and reduction, should be balanced against the
pros and cons of switching.
In addition, we have used the following terminology:
‘Not recommended’ means that it is wise to consider a different
TKI and/or strategy, unless there is a compelling clinical reason not
to do so.
‘Not advisable’ means that it is most unwise to pursue this
strategy, and it is very unlikely that there will be a clinical scenario
in which this does not apply.
In practice, these recommendations cannot be dogmatic, and
must be informed by many variables such as disease phase,
numbers of prior treatment lines, and TKI and stem cell
transplantation availability. Speciﬁc measures are recommended
for special situations, and these will be addressed in the following
system-speciﬁc sections.
SPECIFIC SYSTEMS
Vascular AEs
Vascular events leading to ischaemic heart disease (IHD),
ischaemic cerebrovascular events (ICVE) or peripheral arterial
occlusive disease (PAOD) have become an emerging new type of
toxicity in CML patients treated with ponatinib or nilotinib.24
Pooled data from multiple trials indicate the importance of dose
intensity of ponatinib for the occurrence of vascular adverse
events25 which also includes—in contrast to nilotinib—an
increased risk for venous thrombosis.26 Vascular events from
ponatinib therefore seem to be more common and qualitatively
different from those seen with nilotinib and sequential therapy
with these two agents may confer the highest risk.27 The available
data do not indicate an elevated risk of arterial events in patients
treated with imatinib, bosutinib or dasatinib in any of the phase 3
trials with these agents.4,7,9,22,28–30
Peripheral arterial occlusive disease
Incidence and severity: Although we have no data from direct
comparisons between second generation (2G) TKIs, the data
coming from randomized trials between these vs imatinib suggest
that the excess risk of peripheral arterial occlusive disease (PAOD)
appears to be highest with ponatinib, then with nilotinib, and
almost negligible with the rest.3,23,29,31–52 The actual increment of
risk is not known, because the trials were not designed to assess
ELN recommendations for adverse events in CML
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this point, and vascular risk factors were not properly assessed
before or during the treatment (Table 1).
Predisposing factors and kinetics: Both with ponatinib and
nilotinib, higher doses seem to be associated with more
risk.3,23,31 In addition, patients developing PAOD frequently
(though not always) have pre-existing cardiovascular risk
factors.3,32,33,53,54 Although the vast majority of documented cases
of PAOD occurred within the ﬁrst 48 months of therapy, some
have been seen as early as 4 months, or as late as 5 years.
Preventive measures: As PAOD may be irreversible, prevention
and early detection is important. The cardiovascular risk score
before and while on therapy with TKIs should be documented
based on national or international guidelines55 and should include
palpation of peripheral pulses. We strongly recommend perform-
ing either the ankle–brachial index (ABI) or duplex ultrasonogra-
phy to assess asymptomatic PAOD in all newly diagnosed patients
with CML aged over 65 years56 and in younger patients in the
presence of cardiovascular risk factors or symptoms suggestive of
claudication. We recommend to obtain baseline parameters of
fasting glucose, HbA1c, lipids (cholesterol, low- and high-density
lipoprotein (LDL and HDL) and triglycerides), and creatinine, and
to repeat these parameters every 6–12 months when a
therapeutic regimen including ponatinib or nilotinib is chosen.
The frequency of repeat monitoring will depend on the baseline
results; we advise to repeat ABI (or duplex ultrasonography) every
6–12 months in patients under treatment with ponatinib or
nilotinib, if necessary under the guidance of a vascular surgeon or
analogous specialist. Diabetic patients need a more meticulous
approach. Statins or low-dose aspirin should only be given if there
is a classical cardiovascular indication.
Ischaemic heart and cerebrovascular disease. The presently
published data on IHD or ICVE in TKI recipients are scarcer. As
both IHD and ICVE have been observed at similar frequencies in
patients receiving any of the currently available ﬁrst-line drugs
(imatinib, nilotinib, dasatinib), a recommendation to exclude any
of these drugs for the ﬁrst-line treatment of patients with a history
of IHD or ICVE cannot currently be made. However, given the
similar pathogenesis of PAOD, IHD and ICVE, haematologists
prescribing ponatinib or nilotinib must be aware of the higher
cardiovascular toxicity proﬁles of these drugs and they must be
used with caution.
Choice of TKI depending on cardiovascular risk factors. There is no
absolute contraindication for using any given TKI if comorbidities
are considered. In more advanced disease, the balance between
efﬁcacy and toxicity alters and this may modify the choice of TKI.
The more advanced the disease, the more important is efﬁcacy as
the main variable when choosing TKI. In ﬁrst-line treatment of
chronic phase CML in patients at very high risk of cardiovascular
disease, imatinib or dasatinib are preferred options. In such
patients, nilotinib is not recommended, and should be indicated
only after careful consideration of risk factors, severity and
expected beneﬁt of CML treatment. In low or moderate
cardiovascular risk patients, any TKI can be considered. In patients
with known PAOD before TKI therapy, a widely used staging
system is the Rutherford classiﬁcation57 which deﬁnes mild,
moderate and severe forms of PAOD. In any Rutherford stage,
ponatinib is not advisable, and nilotinib is not advisable if prior
PAOD is severe. However, in patients with only mild to moderate
preexisting PAOD, nilotinib may be prescribed with caution and
after balancing the individual risk proﬁle of alternative TKIs. In all
cases, correction of all the cardiovascular risk factors is recom-
mended; although there is no evidence that doing so mitigates or
diminishes the vascular risk of ponatinib or nilotinib. In any case,
TKI therapy cannot be delayed.
Management of vascular problems. Management recommenda-
tions regarding arterial events should be considered provisional.
They are driven by both the potentially irreversible nature of
arterial damage58 (and thus the need to prevent this complica-
tion), and also by the present and foreseeable lack of data from
prospective clinical trials on how to manage vascular issues. We
suggest taking into consideration the status of response, the BCR-
ABL1 mutation status (for example, the presence of the T315I
mutation) and the grade and history of PAOD as well as
information on previous cardiovascular disease.
Management of PAOD emerging on TKI treatment. Optimal
management of newly emerging PAOD while on TKI therapy is
affected by the depth of response and severity of PAOD. For the
purpose of the different treatment strategies suggested here, we
deﬁne severe PAOD as any type of disease that requires medical
and interventional treatment. With regard to depth of response,
we here deﬁne a stable deep molecular response as MR4 (BCR-
ABL1 ⩽ 0.01% on the international scale, IS) or better response for
at least 18 months. This stratiﬁcation is based on the fact that
most of the presently ongoing or future discontinuation trials are
using MR4 or MR4,5 (BCR-ABL1 ⩽ 0.0032% IS) as entry criteria.
In patients with emergent mild PAOD while on ponatinib or
nilotinib, switching to an alternative TKI is recommended, based
on the patient’s response and comorbidities. If PAOD is moderate
or severe, switching should be done without delay. In addition,
medical and invasive management of PAOD in these patients
should follow local guidelines. Since there are no data indicating
an elevated risk of PAOD in CML patients receiving imatinib,
dasatinib or bosutinib, we at present do not recommend any
speciﬁc modiﬁcation of TKI therapy in patients developing PAOD
on these TKI. In these patients PAOD should be exclusively
managed according to local recommendations.
Management recommendations for emergent IHD and ICVE. In
patients in whom IHD or ICVE occur while on any TKI, optimal care
of the cardio- or cerebrovascular AE must be provided. Baseline
and follow-up electrocardiogram (ECG) and baseline echocardio-
graphy are advised, and a switch to an alternative TKI may be
considered if the presently administered TKI is suspected as
causal.
Cardiological adverse events
Cardiac function. Despite an initial report of in vitro imatinib-
induced damage to cardiac myocytes,59 several clinical studies
covering several thousand patients have been unable to
demonstrate an excess incidence of cardiomyopathy in TKI
recipients with either CML or gastrointestinal stromal tumours
(GIST) which are also amenable to TKI treatment. Clinical trials are
listed in Table 2.60–68 So far, clinical studies with nilotinib and
dasatinib also do not reveal direct cardiotoxic effects.3,37,60,69,70
Ponatinib has a black box warning because of an 8% reported
incidence of heart failure.
Cardiac rhythm alterations. A summary of the effect of TKIs on QT
interval was published in 2013.70 TKIs have the potential to
prolong the QT interval of the ECG, through inhibition of the hERG
subunit of the potassium channel, although in vivo effects have
been predominantly reported with imatinib and nilotinib.71 The
exception seems to be ponatinib, which inhibited hERG at
concentrations above 1 μM, substantially in excess of the steady-
state maximal concentrations observed in patients treated at the
clinical dose of 45 mg.72 An update of data of TKIs within clinical
studies73–76 is given in Table 3. The results of a QT study in healthy
ELN recommendations for adverse events in CML
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volunteers have demonstrated a relationship between nilotinib
serum concentration and QTcF interval prolongation. Up to now
no torsade de point cases were reported with nilotinib but some
sudden deaths occurred within clinical trials potentially associated
to this effect, and this led to a transient box warning in the United
States.
Prevention of cardiac problems
Cardiac function monitoring: Currently, there is no need to
monitor heart function during imatinib therapy. For dasatinib,
nilotinib and bosutinib, caution is necessary, as reports on cardiac
toxicity may arise. Echocardiography has a low power for
detecting subclinical toxicity, but brain natriuretic peptide has
excellent negative predictive value for left ventricular dysfunction
and a normal value can be informative in clinical practice.77
Monitoring of cardiac function is mandatory for ponatinib (see
above).
ECG monitoring: It is sensible to recommend an ECG before
initiating any TKI therapy, because most of the TKIs affect the QT
interval, and there is a high individual variability of changes in
QTc. In case of QTc prolongation of4440 ms or when ponatinib is
used, frequent monitoring is recommended, and this should be
sustained at 3–6 monthly intervals if there is a prolongation of
430 ms from baseline. In the case of prolongation of 450 ms
from baseline or QTc 4500 ms, treatment cessation and
cardiological advice are recommended. As concomitant adminis-
tration of strong CYP3A4 inhibitors signiﬁcantly increases the
serum concentration of TKIs, appropriate management of
concomitant medications is essential.
Nilotinib should be avoided in the long QT syndrome, or where
there are concomitant drugs that prolong the QT interval.
Hypokalaemia or hypomagnesaemia should be corrected prior
to nilotinib use and these electrolytes should be monitored
periodically. An ECG should be obtained to monitor QTc at
baseline, then 7 days after start, after dose increase and
periodically. Food should be avoided 2 h before and 1 h after
dosing. Nilotinib should not be given to patients with risk of
arrhythmias.
Management of cardiac adverse events
Management of rhythm disturbances and QTc prolongation: The
development of arrhythmias should prompt the interruption of
the TKI and consultation with a cardiologist. In the case of
nilotinib, it must be stopped permanently.
Emergent QTc prolongation should prompt a review of
potential TKI interactions and measurement of electrolytes.
In the case of QTc 4440 ms or prolongation of 430 ms from
baseline, strict monitoring is recommended (at least weekly). In
the case of QTc 4500 ms or prolongation of 450 ms from
baseline, temporary treatment cessation is recommended, fol-
lowed by weekly ECG and TKI resumption when QTc ⩽ 450 ms
in two consecutive ECGs. In the case of nilotinib treatment,
resumption at a lower dose is recommended once the QTc falls in
this way, without subsequent re-escalation.
Other cardiac problems and hypertension: Other cardiac pro-
blems should be managed following the aforementioned general
rules of non-haematological toxicity. Peripheral oedema could
be a sign of cardiac dysfunction, and treatment must be
aetiologically based. However, in most cases ﬂuid retention is
not associated with cardiac dysfunction, and is normally manage-
able and reversible with diuretics. Arterial hypertension must be
actively treated, especially in recipients of ponatinib, which has
been associated with hypertension in 9% of recipients by
12 months, being severe in 2%. In all cases, early detection and
management of hypertension according to local/national guide-
lines is important.
Pulmonary adverse problems
Pleural effusion
Incidence and severity: The risk of effusions exists with all the
TKIs currently approved for ﬁrst-line CML treatment (imatinib,
dasatinib and nilotinib), but is much higher with dasatinib.
Common symptoms of effusions include signiﬁcant dry cough,
fatigue, chest pain and dyspnoea78,79 With imatinib treatment
very few cases have been reported, usually associated with
pericardial effusions or associated with advanced phases and
doses of imatinib above 400 mg daily.80 The risk of pleural effusion
with nilotinib in ﬁrst line is also very low.3 With dasatinib, in
patients resistant to imatinib, the incidence of reported pleural
effusions ranges from 14 to 39%, higher in more advanced
phases.81–84 The frequency appears to be related to the dose, both
in advanced phase85,86 and in chronic phase.87 In the DASISION
trial, at 5 years of follow-up the incidence was 28% as compared
with o1% with imatinib.69 The risk of appearance of pleural
Table 3. Data for QTc prolongation for TKIs
TKI Studies Increase of QT interval Result absolute value Conclusion
Imatinib ENESTnd imatinib 400 mg (n= 280)3 4480 ms: 0.7%
4500 ms: 0.4%
Symptomatic prolongation in
2.5%
Nilotinib 2101 CP and APa 430 ms: 29.4%
460 ms: 1.3%
4450 ms: 10.2%
4480 ms: 1.1%
4500 ms: 0.5%
No episode of torsade de
pointes
Nilotinib ENESTnd, nilotinib 300 mg (n= 279)3 4480 or 500 ms: 0% Symptomatic prolongation in
1.8%
Bosutinib Healthy adult
subjects73 and BELA trial74
No subjects had change from baseline
430 ms
No subjects had
QTcB, QTcF, QTcI or
QTcN 4450 ms.
No clinically relevant
PK/PD relationship was
observed between bosutinib
concentrations and QTc
BELA: no data provided
Ponatinib Phase 1 trial, AP24534-07-10175 On 30 mg dosage: decrease of QT
On 45 mg dosages: Increase of 3.3 ms
Low risk of QT prolongation
Dasatinib 2440 patientsa,76 Maximum mean
Changes in QTcF (90% upper bound CI)
from baseline ranged from 7.0 to 13.4 ms.
4500 ms: 1%
Abbreviations: AP, accelerated phase; CP, chronic phase. aInformation taken from investigator brochure.
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effusion in dasatinib treated patients does not seem to decrease
with time.88 Besides, recurrence of pleural effusion occurs in
roughly 70% of the cases. However, most of the pleural effusions
are mild or moderate, with grade 3/4 reported in 4%19 and low
rates of dasatinib discontinuation due to this side effect during the
ﬁrst year.83 In patients treated with bosutinib in second line,
pleural effusions were detected in 4% by 2 years.21
Kinetics: Pleural effusion needs long-term attention. In second-
line treatment with dasatinib, the median time to appearance is 5–
11 months,89,90 but it can be delayed until 3 years.91 In ﬁrst-line
use, the median time to pleural effusion was 10 months, and most
effusions (89%) occurred more than 8 weeks into treatment;88
although the risk diminishes with time, pleural effusion can occur
throughout treatment.35
Predisposing conditions: In second-line use, previous or con-
comitant cardiac disease and hypertension seem to be the
most common predisposing conditions.78,79 Also, twice daily
scheduling,78 advanced phases, hypercholesterolaemia, a previous
history of auto-immune disorders and skin rashes experienced
during imatinib therapy have been identiﬁed as risk factors.79
Older age is also associated with pleural effusion,89 and in patients
older than 60 years, the presence of concomitant pulmonary
disease, the initial daily dose of dasatinib (140 mg vs 100 mg),90
and a higher comorbidity index92 were associated with pleural
effusion. As well as knowing the situations that increase the risk of
pleural effusion, patients and doctors must be vigilant in the
presence of cough, dyspnoea or chest pain, and these symptoms
should prompt a chest X-ray.
Management of pleural effusions: Management of dasatinib-
related pleural effusions includes treatment suspension or
reduction of the dose, with or without steroids and diuretics. In
rare instances, usually of grade 3–4, more invasive measures such
as thoracocentesis are necessary to resolve the effusion.19,78,89
Pleural effusions are potentially reversible after discontinuation of
dasatinib and the administration of steroids and diuretics. They
can also be recurrent. Whereas after resolution of the ﬁrst episode,
the drug could be resumed at the same dose, in the case of a
second episode it is advisable to reduce the dose to the next
lower level (for example, 80 mg from 100 mg/day). In the case of
further relapses, either stepwise lowering the dose down to
50 mg/day or switching to another TKI are reasonable options. If
the relapse is symptomatic, even if during the ﬁrst occurrence of
an effusion, switching is the preferred option. A regimen of 5 days
on, 2 days off is under investigation.93
Pleural effusions emerging on second-line bosutinib therapy
may also occur; a similar management approach to that taken
with dasatinib seems to be reasonable.
Pulmonary arterial hypertension
Incidence and severity: Pulmonary arterial hypertension (PAH)
has been reported with the use of dasatinib94–97 at an estimated
incidence of 0.45% and a median delay between drug initiation
and PAH diagnosis of 34 months (range 8–48 months). At PAH
diagnosis, most patients had severe clinical, functional and
haemodynamic signs of failure, some of them requiring vasoactive
drugs and management in the intensive care unit.97 Clinical and
functional improvements were usually observed after discontinu-
ing dasatinib; however, the majority of patients failed to
demonstrate complete haemodynamic recovery and two patients
died at follow-up.97
Prevention and management: The presence of dyspnoea and
syncope not explained by pleural effusion should prompt the
suspicion of PAH. Although rare, it is potentially fatal. Prompt
withdrawal of dasatinib may totally or partially reverse PAH, but
pharmacologic treatment may be needed,94,95 and referral to a
suitable specialist is mandatory.
Pneumonitis. Pneumonitis is a quite rare complication, and it has
been described mostly with imatinib98,99 and in Asian countries.
It can be reversible100 or not.101 Both hypersensitivity pneumonitis102
and eosinophilic types have been described. In second-line
therapy with dasatinib 70 mg twice daily, 17% developed lung
parenchyma changes with either ground glass or alveolar
opacities or septal thickening.103 The treatment for imatinib-
induced pneumonitis is to discontinue the medication and
administer glucocorticoids. Although there are a few cases of
successful retrial with imatinib,101 switching to nilotinib or
bosutinib are the preferred options if the pneumonitis is not mild.
Hepatobiliary AEs
A comprehensive meta-analysis of 12 published studies suggested
that there is a signiﬁcant overall increase in the odds of
developing high-grade (grade 3 or above) hepatotoxicity with
the use of TKIs in cancer compared with the control arms.104 In
pre-approval clinical trials of TKIs, hepatotoxicity manifested itself
as low-grade increases in serum alanine (ALT) and/or aspartate
transaminases (AST) in 25–35% of patients and as high-grade
(grade 3 or above) increases in these transaminases in ~ 2%. As
shown in Tables 4, 5a and b, the incidences of both all-grade and
high-grade transaminase increases vary widely between agents
and the potential for serious hepatotoxicity with ponatinib is
believed to be sufﬁciently high as to require a boxed label
warning1,2,5,21,22,46,105–107
Table 4 presents a summary of kinetics in principal (registration)
clinical trials of hepatotoxicity. In the majority of cases, the time to
onset of increased ALT and AST is 2–8 weeks after initiating
therapy. Exceptionally, however, it may be delayed as in a few
cases following treatment with imatinib. The median time to
onset of ALT or AST elevation following ponatinib was 46 days
(range 1–334 days).108
There have been few reports of hepatic failure with some TKIs
and in general, fatalities from TKI-induced hepatotoxicity are rare,
reported so far with imatinib and ponatinib. In most patients,
lesions showed necrotic hepatitis associated with a non-speciﬁc
inﬂammatory inﬁltrate; patients with fulminant hepatitis had a
massive viral hepatitis-like necrosis compatible with an inﬂamma-
tory idiosyncratic mechanism.109–115
Hyperbilirubinaemia is the most frequent laboratory AE
observed with nilotinib, but in most cases does not represent
true hepatotoxicity. Pharmacogenetic analysis demonstrated that
genotypic differences may account for an increased risk of
hyperbilirubinaemia in some nilotinib-treated patients.116
Prevention. Imatinib is metabolised by cytochrome P450, espe-
cially CYP3A4 and (where functional) CYP3A5. Therefore, an
increase in toxic metabolites may occur where there is con-
comitant use of enzymatic inducers like alcohol117 or therapeutic
agents such as roxythromycin.114 Nilotinib and to a lesser extent
other TKIs have the potential to inhibit UDP glucuronosyltransfer-
ase A1 (UGT1A1) and this may contribute to TKI-related
unconjugated hyperbilirubinaemia. This must be taken into
account in patients with Gilbert’s syndrome, in whom this
bilirubin transporter is congenitally impaired. When acetamino-
phen (paracetamol) glucuronidation is impaired, the risk of
acetaminophen hepatotoxicity is higher. Caution is also advised
when using imatinib and acetaminophen concomitantly.118
Management. Management of TKI-induced hepatotoxicity
should be in line with general principles. In the case of grade 3
toxicity, we prefer to withhold therapy until grade o2, and then
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resume at a lower dose, or to switch to another TKI. In the face of
grade 4 toxicity, switching to another TKI is mandatory.
After discontinuation of imatinib for hepatotoxicity, liver
function typically resolves fully with normalisation of liver tests
in 7 weeks (range 2− 20 weeks). However, fatal liver injury has
occurred in some patients, especially in those treated by
acetaminophen or with hepatitis B virus infection. In several
published cases, early administration of glucocorticoid therapy
(prednisone or methyl-prednisolone) resulted in rapid and
complete hepatic recovery119 and in a few case reports they have
enabled the re-introduction of imatinib in patients who develop
recurrent hepatotoxicity, usually at reduced doses. Steroids used
in these case reports included oral prednisone 25–30 mg daily
tapered over 5–8 months. In potentially fatal hepatic cases liver
transplantation has been needed.120
Cross-intolerance. Available data on cross-intolerance of hepato-
toxicity to other TKI are scarce. In patients treated previously with
imatinib, with grades 3–4 or persistent grade 2 liver toxicity, none
developed this degree of liver toxicity with subsequent nilotinib
therapy.109,121 Nilotinib was used without liver toxicity in a patient
undergoing liver transplantation for fulminant liver failure
associated with imatinib.120 Dasatinib has been safely used after
a patient receiving imatinib and developing liver toxicity was
successfully treated with glucocorticoids.122
Endocrine and metabolic abnormalities
Hyperglycaemia and glucose metabolism
Incidence and severity: In patients resistant or intolerant to
imatinib and treated with nilotinib, grade 3–4 hyperglycaemia has
been reported in 12% of chronic phase and 6.7% of accelerated
phase CML patients enroled in phase II studies.123,124 In the ENACT
trial, hyperglycaemia occurred after 7 days from start of nilotinib,
with a median duration of 21 days.125 In ﬁrst-line treatment,
randomised studies have shown that the incidence of grade 3–4
hyperglycaemia with nilotinib is about 6, vs 0% with imatinib.3 In
diabetic patients treated with nilotinib, 31% changed antidiabetic
treatment and 60% developed grade 3–4 hyperglycaemia, but
none developed ketoacidosis, hyperosmolar events or cardiovas-
cular complications.126 In normoglycaemic patients, excluding
patients with diabetes at baseline, 20.1% developed diabetes by 3
years vs 8.9% with imatinib. In the whole series of patients, none
had discontinued due to this side effect and o2% were started
with antidiabetic drugs.127 In contrast, dasatinib has been shown
to reduce fasting glucose.128,129
Prevention of glucose alterations: Hyperglycaemia during niloti-
nib therapy is frequently observed in the ﬁrst 2–3 weeks of
administration and also the hypoglycaemic effect of dasatinib has
been described as an early event.123–129 Diabetic patients
receiving TKIs may need their diabetes monitored more frequently
in case their antidiabetic treatment needs adjustment. Patients
with type II controlled diabetes or pre-diabetes may receive
nilotinib or other available TKIs but with strict monitoring of
fasting glucose and glycosylated haemoglobin and review of
therapy by an appropriate specialist. In the case of persistent
fasting glucose level higher than 126 mg/dl (7.0 mmol/l) or a
glycosylated haemoglobin level higher than 6.5%, a temporary
reduction or discontinuation and specialist referral are
recommended.
Management of diabetes mellitus: General recommendations
apply to the treatment of diabetes emergent during TKI, with
special attention when the patient is receiving nilotinib. It is worth
noting that diabetic patients treated with nilotinib as ﬁrst line
developed hyperglycaemia almost constantly, half of them of
grade 3–4, but no major complications related to diabetes (for
example, hyperosmolar coma, ketoacidosis, hospitalisation) were
detected, and 74% of patients did not change antidiabetic
treatment. Though follow-up was short, none of the patients
developed a cardiovascular complication.126
Effects on lipid metabolism
Incidence and severity: In the ENESTnd trial of ﬁrst line
therapy,130 nilotinib is associated with hypercholesterolaemia in
22% of patients, compared with 3% of imatinib recipients; indeed,
imatinib may reduce the total level of cholesterol and
tryglycerides.131–133 There were no cases of hypercholesterolaemia
grade 3–4 in either arm.130 In a recent small study, the median
increase of LDL-cholesterol after nilotinib treatment was 33 mg/dl
at 3 months. The median decrease of triglycerides was of the same
magnitude in the same period.134 In phase I trial of ponatinib in
Table 4. Liver toxicity (Shah et al., modiﬁed)108
Drug Major indication Incidence of ALAT/ASAT elevations (%)a Latency to onset of
hepatic injury
Cases of hepatitis
or hepatic failure
Fatal cases of
hepatic failure
All grade Grade 3-4
Imatinib CML
ALL
HS
GIST
6–12 3–6 Median 12–77 days Yes Yes
Dasatinib CML
ALL
50 1–9 No information No No
Nilotinib CML 35–62 1–4 No information Yes No
Bosutinib CML 20 4–9 Median 30-33 days Yes No
Ponatinib CML
ALL
56 8 Within 1 week Yes Yes
Abbreviations: ALAT, alanine aminotransferase; ALL, acute lymphoblastic leukaemia; ASAT, aspartate aminotransferase; CML, chronic myeloid leukaemia;
GIST, Gastointestinal stromal tumours; HS, Hypereosinophilic syndrome. Side effects, grading according to NCI-CTC (Common Terminology Criteria for
Adverse Events of the National Cancer Institute). aValues shown are best estimates computed from pre-approval of European Union Medicines Agency.
European public assessment reports assessment history and product information (http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/
landing/epar_searc.jsp&mid=WC0b01ac058001d124) and US Food and Drug Administration. Product reviews and labels (http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm). Regulatory reviews and labels of the TKI concerned from data across a number of trials and indications when
appropriate.
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resistant disease, hypertriglyceridaemia was reported in 12% of
patients at all grades, but none of the patients experienced a
grade 3/4 event.135 No evidence of impaired lipid metabolism with
dasatinib or bosutinib have been reported up to now.
Prevention and management: An increased cholesterol level
with nilotinib has been reported as an early effect,134 and has
been associated with PAOD.53,134,136 It is therefore suggested to
test the lipid proﬁle at baseline and during the course of
treatment, and in the event of persistent hypercholesterolaemia
(higher than 240 mg/dl (6.2 mmol/l), considered high risk accord-
ing to American Association of Clinical Endocrinologists (AACE)
guidelines), to add an appropriate statin in line with regional/
national guidelines.
Phosphate and calcium metabolism
Incidence and severity: Hypophosphataemia was ﬁrst described
with imatinib, with an early onset in younger patients treated with
higher doses.137 As a consequence of hypophosphataemia, a
reduced serum calcium level and increased renal phosphate
excretion with increased serum levels of parathyroid hormone
have been reported.138 In the long-term, 50% of adults
developed decreased bone mineral density.139 In the ﬁrst-line
trials ENESTnd and DASISION, hypophosphataemia (mostly
mild) was seen in 49% and 25% of patients treated with
imatinib, respectively, and in 33% and 7% of those treated with
nilotinib or dasatinib.2,5,130 Hypocalcaemia is less common than
hypophosphataemia.
Prevention and management: The serum phosphate and cal-
cium level should be tested before and during treatment with
imatinib and nilotinib every month for the ﬁrst 3 months and then
every 3–6 months thereafter. Prompt correction of hypopho-
sphataemia and hypocalcaemia may be necessary if clinically
indicated. Hypovitaminosis D must be corrected. Long-standing
hypophosphataemia and hyperparathyroidism are indications for
bone densitometry.139
Other endocrine abnormalities. In patients treated with imatinib,
nilotinib and dasatinib, thyroid abnormalities were detected in
25%, 55% and 70% of patients, respectively.140 Hypothyroidism is
more common than hyperactivity, and it responds to hormone
supplementation.140 Gynaecomastia has been reported in 6%
patients with imatinib, mostly associated with diminution of
testosterone levels141 and dasatinib.142
Haematological adverse events: myelosuppression
General comments. Myelosuppression developing during TKI
treatment of CML is very common. It is due to the combined
effect of the suppression of the leukaemic clone and the inhibition
of non-leukaemic haematopoiesis, which is greatly reduced at
CML diagnosis.143 After TKI-induced reduction of leukaemic
haematopoiesis, normal stem and progenitor cells need time to
recover from pre-existing suppression by the malignant clone and
to re-populate the bone marrow.
This interpretation is supported by several observations: ﬁrst,
myelosuppression is almost always limited to the ﬁrst weeks or
months of treatment. Second, the incidence of grade 3 or 4
myelosuppression is predominant at the initiation of treatment
and decreases substantially with longer exposures to any TKI.
Third, haematological side effects of TKIs are (mostly) dose-
dependent, reversible on treatment cessation or dose reduction,
and affect all three lineages to a variable degree.15,16,144,145 Thus,
myelosuppression is an expression of efﬁcacy rather than a true
toxicity, and it is rare once a remission has been achieved.
Nevertheless, haematological toxicity is important because it is
the major cause of treatment discontinuation/interruption andT
ab
le
5a
.
Li
ve
r
to
xi
ci
ty
o
f
TK
I
u
se
d
as
ﬁ
rs
t-
lin
e
th
er
ap
y
(im
at
in
ib
,n
ilo
ti
n
ib
,b
o
su
ti
n
ib
an
d
d
as
at
in
ib
)
So
ur
ce
IR
IS
TK
I,
d
o
sa
g
e
(n
)
Im
at
in
ib
40
0
m
g
Q
D
(N
=
55
3)
M
ed
ia
n
d
u
ra
ti
o
n
,m
o
n
th
s
A
t
18
m
o
n
th
s1
Ye
ar
1–
2
Ye
ar
3–
4
4
4
Ye
ar
s
B
y
5
ye
ar
s4
6
A
E
G
ra
d
e
A
ll
g
ra
d
es
G
ra
d
e
3/
4
G
ra
d
e
¾
G
ra
d
e
3/
4
G
ra
d
e
3/
4
G
ra
d
e
3/
4
El
ev
at
ed
A
LT
43
.2
%
5.
1%
5%
o
1%
0%
5%
El
ev
at
ed
A
ST
So
ur
ce
EN
ES
Tn
d2
BE
LA
2
2
D
A
SI
SI
O
N
5
TK
I,
d
o
sa
g
e
(n
)
N
ilo
ti
n
ib
30
0
m
g
tw
ic
e
d
ai
ly
(n
=
27
9)
N
ilo
ti
n
ib
40
0
m
g
tw
ic
e
d
ai
ly
(n
=
27
7)
Im
at
in
ib
40
0
m
g
d
ai
ly
(n
=
28
0)
B
o
su
ti
n
ib
50
0
m
g
d
ai
ly
(n
=
24
8)
Im
at
in
ib
40
0
m
g
d
ai
ly
(n
=
25
1)
D
as
at
in
ib
10
0
m
g
d
ai
ly
(n
=
25
8)
Im
at
in
ib
40
0
m
g
d
ai
ly
(n
=
25
8)
M
ed
ia
n
d
u
ra
ti
o
n
,m
o
n
th
s
14
14
24
A
E
g
ra
d
e
A
ll
g
ra
d
es
G
ra
d
e
3/
4
A
ll
g
ra
d
es
G
ra
d
e
3/
4
A
ll
g
ra
d
es
G
ra
d
e
3/
4
A
ll
g
ra
d
es
G
ra
d
e
3/
4
A
ll
g
ra
d
es
G
ra
d
e
3/
4
A
ll
g
ra
d
e
G
ra
d
e
3/
4
A
ll
g
ra
d
es
G
ra
d
e
3/
4
El
ev
at
ed
A
LA
T
66
%
4%
73
%
9%
20
%
2%
69
%
22
%
29
%
3%
—
0.
5%
—
2%
El
ev
at
ed
A
SA
T
40
%
1%
48
%
3%
23
%
1%
56
%
11
%
27
%
3%
—
0.
5%
—
1%
El
ev
at
ed
to
ta
l
B
ili
ru
b
in
53
%
4%
62
%
8%
10
%
o
1%
—
—
—
—
—
—
—
—
A
b
b
re
vi
at
io
n
s:
A
LA
T,
al
an
in
e
am
in
o
tr
an
sf
er
as
e;
A
SA
T,
as
p
ar
ta
te
am
in
o
tr
an
sf
er
as
e.
Si
d
e
ef
fe
ct
s,
g
ra
d
in
g
ac
co
rd
in
g
to
N
C
I-C
TC
(C
o
m
m
o
n
Te
rm
in
o
lo
g
y
C
ri
te
ri
a
fo
r
A
d
ve
rs
e
Ev
en
ts
o
f
th
e
N
at
io
n
al
C
an
ce
r
In
st
it
u
te
).
ELN recommendations for adverse events in CML
JL Steegmann et al
1656
Leukemia (2016) 1648 – 1671 © 2016 Macmillan Publishers Limited
dose reduction, since a patient with chronic phase CML cannot be
put at risk of dying from infection or bleeding144–147 Thus, the
management of cytopenias lies mainly in tight monitoring of
blood counts.
Incidence of myelosuppression
Limitations of this analysis: Many papers have reported the
haematological toxicity of TKIs, in different disease phases (chronic
phase or advanced disease), in different lines of therapy and at
Table 6. Myelosuppression in CML patients treated with TKIs
Reference Treatment Toxicity Number of patients Number of patients (%)
with grade 3/4 toxicity
1,2,4,6,22,155–157,159 First line, imatinib 400 mg daily Anaemia 2232 109 (4.9%)
Thrombocytopenia 2232 227 (10.2%)
Neutropenia 1911 330 (17.3%)
6,148,151,154,157 First line, imatinib 400 mg twice daily Anaemia 946 59 (6.2%)
Thrombocytopenia 946 152 (16.1%)
Neutropenia 442 152 (34.4%)
2,159 First line, nilotinib 300 mg twice daily Anaemia 412 14 (3.4%)
Thrombocytopenia 412 62 (15.0%)
Neutropenia 412 61 (14.8%
2,159 First line, nilotinib 400 mg twice daily Anaemia 413 12 (2.9%)
Thrombocytopenia 413 42 (10.2%)
Neutropenia 413 38 (9.2%)
4,156,158 First line, dasatinib, 100 mg daily Anaemia 442 51 (11.5%)
Thrombocytopenia 442 77 (17.4%)
Neutropenia 442 86 (19.4%)
22 First line, bosutinib 500 mg daily Anaemia 248 15 (6.0%)
Thrombocytopenia 248 35 (14.1%)
Neutropenia 248 27 (10.8%)
105,124,149 Second line, nilotinib 400 mg twice daily Anaemia 321 35 (10.9%)
Thrombocytopenia 1743 409 (23.5%)
Neutropenia 1743 299 (17.2%)
87 Second line dasatinib 100 mg daily Anaemia 166 16 (9.6%)
Thrombocytopenia 166 37 (22.3%)
Neutropenia 166 55 (33.1%)
84,87,150 Second line, dasatinib 70 mg twice
daily or 140 mg daily
Anaemia 717 138 (19.2%)
Thrombocytopenia 818 386 (47.2%)
Neutropenia 818 376 (45.8%)
29 Second line, bosutinib 500 mg daily Anaemia 288 40 (13.9%)
Thrombocytopenia 288 69 (23.9%)
Neutropenia 288 49 (17.0%)
107 Third line, bosutinib 500 mg daily Anaemia 118 9 (7.6%)
Thrombocytopenia 118 30 (25.4%)
Neutropenia 118 22 (18.6%)
23 Third line, ponatinib 45 mg daily Anaemia 270 16 (5.9%)
Thrombocytopenia 270 86 (31.8%)
Neutropenia 270 38 (17.8%)
Side effects, grading according to NCI-CTC (Common Terminology Criteria for Adverse Events of the National Cancer Institute).
Table 5b. Liver toxicity of TKI used in CML as second-line therapy
Source CAMN107A2101105 CA180034106 3160A4-200-WW21 3160A4-200-WW107
TKI dosage (n) Nilotinib 400 mg twice daily
(n= 321)
Dasatinib100 mg daily
(n= 165)
Bosutinib 500 mg daily
(n= 286)
Bosutinib 500 mg daily
(n= 118)
Median duration, months 24 22 25 9
Treatment line Second line Second line Second line Third/fourth line
AE grade All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4
Elevated ALAT 69% 4% — — 22% 9% 15% 6%
Elevated ASAT 55% 3% — — 19% 4% 8% 3%
Elevated total Bilirubin 72% 7% — — — — — —
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase. Side effects, grading according to NCI-CTC (Common Terminology Criteria
for Adverse Events of the National Cancer Institute).
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different doses. In chronic phase, while there are ﬁrst-line studies
comparing imatinib with other TKIs, there are no comparison
studies between individual 2G TKI. This also applies for studies in
second and subsequent lines. In advanced phases, data are scarce,
and myelosuppression, though more common in chronic phase,
is difﬁcult to interpret because it is very common in these
phases per se.
Regrettably, haematologic toxicity has always been reported as
a percentage of patients with grade 1/2 and with grade 3/4
toxicity, which is not very useful, since grade 1 is irrelevant, while
sustained grade 2 can be more important than occasional grade 3.
The reported incidence of all grades of toxicities varies over such a
wide range, from 2 to 90%, thus data on the incidence of all
grades of toxicities are difﬁcult to interpret.
Available data: In chronic phase patients, data on haematologic
toxicity are available in at least 20 company-sponsored and 10
investigator-sponsored studies, reporting on a total of 8417
patients.1–6,11,19,20,22,23,29,84,87,105,124,148–159 There are variations of
up to threefold in the reported incidence of grade 3/4 toxicities, so
we have pooled together the data from different studies, in order
to offer a comprehensive overview of haematologic toxicities
(Table 6). Results of randomised trials in ﬁrst line comparing
imatinib with other TKIs are given in Table 7.
Myelosuppression of grade 3 or 4, leading to transient (rarely
permanent) treatment discontinuation, was more frequent in
patients with resistant disease, where the reservoir of normal
haematopoietic progenitors may be diminished. Neutropenia is
most frequent, followed by thrombocytopenia and anaemia.
Clinical features associated with a greater risk of myelosuppres-
sion include an increased percentage of bone marrow blasts and a
lower haemoglobin level. In second- and third-line therapy, the
incidence of grade 3/4 anaemia ranged between 5.9% (ponatinib
45 mg daily) and 19.2% (dasatinib 70 mg twice daily or 140 mg
once daily), that of grade 3/4 thrombocytopenia between 23.5%
(nilotinib 400 mg twice daily) and 47.2% (dasatinib 70 mg twice
daily or 140 mg once daily), and that of grade 3/4 neutropenia
between 17.0% (bosutinib 500 mg once daily) and 45.8%
(dasatinib 70 mg twice daily or 140 mg once daily).
In ﬁrst-line therapy, we can conclude that imatinib 400 mg once
daily induces more neutropenia than nilotinib (at either 300 or
400 mg each twice daily) or bosutinib 500 mg once daily, and
slightly less than dasatinib 100 mg daily. A differential effect
between TKIs on other lines is less clear, although imatinib
appears to induce slightly less thrombocytopenia and anaemia
than dasatinib. The data listed in Table 6 should be considered
with caution and cannot be compared with a classic chi-squared
test. However, it appears that dasatinib may have greater
haematologic toxicity, and its toxicity is dose- and schedule-
related, as also shown in prospective studies.87
Other variables associated with cytopenias: In contrast to
observations in GIST, in chronic phase CML the haematological
toxicity of imatinib is likely to be dose-related, and has been
shown to be related to plasma drug concentration.160 Interest-
ingly, with nilotinib in ﬁrst line, neutropenia is more frequent at a
dose of 300 mg twice daily than at the higher dose of 400 mg
twice daily, maybe because patients receiving 400 mg twice daily
underwent dose reduction or discontinuation more frequently
because of other AEs.2,3 The haematologic toxicity of imatinib
does not appear to be higher in patients aged more than
65 years.161
Kinetics of cytopenias: Haematological toxicity is almost always
limited to the ﬁrst weeks or months of treatment but late
cytopenias have also been observed. In chronic phase patients,
the peak incidence of myelosuppression is within the ﬁrst
4–6 weeks after starting TKI treatment: the decline of platelets
generally occurs 1–2 weeks later than the decline in neutrophil
count. The incidence of grade 3 or 4 cytopenias is highest at the
initiation of treatment and decreases substantially with longer
exposures to any TKI.15,16,144,145 In fact, the increment of the
incidence of cytopenias beyond the ﬁrst year of therapy is in the
range of 1–2 percentage points, and this is valid for imatinib,
nilotinib, dasatinib and bosutinib.2–4,22,29,74,162
Consequences of cytopenias. Haematologic toxicity may cause
infection and bleeding, which can be fatal. The causes of death in
chronic phase are not identiﬁed in all reports. Mortality ﬁgures for
deaths due to sepsis/haemorrhage should be regarded as approx-
imate, because some deaths may have occurred after progression,
and also because in most studies the follow-up was short.
Infections: In ﬁrst-line therapy, deaths due to infection after
dasatinib or imatinib were 1.9% and 0.4%,1,3,4,11,22,30,106 whereas
they were 0% with nilotinib,3,152,153 and bosutinib.22 In second-
and third-line therapy, deaths due to infection after dasatinib and
nilotinib were reported in 1% and 0.07%, respectively.105,124,149
In contrast no deaths due to infection were reported with
bosutinib23,29,107 or ponatinib.23
Dasatinib is more frequently associated with death from sepsis
than other TKIs, and this is also true at 100 mg once daily.4,5,87 It is
worth noting that dasatinib inhibits proinﬂammatory functions of
mature human neutrophils,163 and all TKIs have a potential
immunosuppressive effect (reviewed in refs 15,144,146,147).
Bleeding: In the IRIS study it was reported that the incidence of
bleeding at any grade was 20%, both with imatinib and in the
interferon plus ara-C arm. The incidence of severe bleeding was
almost nil. In other ﬁrst line studies, deaths due to bleeding after
imatinib were 0.4%.1,3,4,11,22,30,106 In contrast, there were no deaths
Table 7. Myelosuppression in the main randomized trials in ﬁrst line
Neutropenia Thrombocytopenia Anemia
All grades (%) Grade ¾ (%) All grades (%) Grade 3/4 (%) All grades (%) Grade 3/4 (%)
ENESTND2 Nilotinib 300 mg twice daily 43 12 48 10 38 3
Imatinib 400 mg daily 68 20 56 9 47 5
DASISION4 Dasatinib 100 mg daily 65 21 70 19 90 10
Imatinib 400 mg daily 52 20 62 10 84 7
BELA22 Bosutinib 500 mg daily 28 11 66 14 80 6
Imatinib 400 mg daily 54 24 62 14 84 7
Side effects, grading according to NCI-CTC (Common Terminology Criteria for Adverse Events of the National Cancer Institute).
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with dasatinib,5 nilotinib,3,152,153 or bosutinib.22 In second line
therapy, clinically relevant dasatinib-related bleeding has been
associated with thrombocytopenia and advanced phases,164 with
an incidence of 25%, severe in 3%.19 With bosutinib, the
corresponding ﬁgures are 5 and 1%, respectively.21 In the case
of ponatinib, bleeding has been seen in 11%, and most bleeding
episodes were not directly related to the drug.165
In second- and third-line treatment, deaths due to bleeding
after dasatinib and nilotinib were reported in 0.9%,87,106,150 and
0.8% of patients, respectively,105,124,149 whereas it was 0.4% with
bosutinib23,29,107 and 0% with ponatinib.23 It must be taken into
account that dasatinib,164,166,167 and to a lesser extent imatinib167
and ponatinib,168 induce platelet dysfunction.
Long-term effects: The long-term consequences of cytopenias
are not well known. In patients previously treated with interferon,
neutropenia developing during the ﬁrst 3 months of TKI therapy
was associated with lower progression-free survival.169 Patients
treated with imatinib who developed anaemia and other
manifestations of myelosuppression were found to have a
signiﬁcantly worse outcome than those with isolated
anaemia.170
Monitoring. In chronic phase, during the ﬁrst 4–6 weeks, blood
counts should be monitored weekly. Later and in absence of
relevant (grade 2–4) cytopenias, the frequency can be reduced to
every 2 weeks or monthly until month 3, depending on the
stability of blood counts. After month 3, monitoring every
3 months is advised. More frequent monitoring is advised for
patients with advanced disease, especially because the dose
intensity is pivotal for optimal response.
Management of myelosuppression. A general principle in the
management of TKI-induced myelosuppression is to balance the
risks and the beneﬁts according to the aggressiveness of CML.
Moreover, the incidence of severe cytopenias varies depending on
the TKI used. Consequently, recommendations for managing
myelosuppression are slightly different for different TKIs in chronic
phase vs advanced phases. Table 8 reports suggestions to manage
severe cytopenias according to the prescribing information and
study protocols.
Management in chronic phase: For all TKIs in chronic phase
patients, in the case of grade 3 or 4 cytopenias, the drug must be
withheld at the ﬁrst episode. In the case of recurrence and
depending on the duration of the ﬁrst episode of cytopenia, the
drug must be restarted at a lower dose, but once a stable
response has been achieved, re-escalation to the target dose
should be considered. With recurrent grade 3–4 cytopenias,
especially in ﬁrst-line chronic phase, switching to an alternative TKI
Table 8. Management of cytopenias
TKI Setting and starting dose Hematopoietic toxicity Dose adjustments for neutropenia and thrombocytopenia
Imatinib CP, 400 mg daily ANC o1.0 × 109/l and/or
platelets o50 ×109/l
(1) Stop imatinib until ANC41.5×109/l and platelets475×109/l4resume starting dose
(2) Recurrence: repeat step 1 and resume at the reduced dose of 300 mg daily
AP and BP, 600 mg
daily
ANC o0.5 × 109/l and/or
platelets o10 ×109/l
(1) Check if neutropenia is related to leukaemia (marrow aspiration or biopsy)
(2) If UNRELATED, reduce imatinib to 400 mg daily
(3) If cytopenia persists 42 weeks, reduce to 300 mg daily
If cytopenia persists for 44 weeks and is still unrelated to leukaemia, stop imatinib
until ANC⩾1×109/l and platelets ⩾20×109/l and resume at 300 mg daily
Nilotinib CP, frontline, 300 mg
twice daily
CP, second line, or AP,
400 mg twice daily
ANC o1.0 × 109/l and/or
platelets o50 ×109/l
(1) Stop nilotinib until ANC41.0×109/l and platelets450×109/l4resume starting dose
(2) If blood counts remain low for42 weeks, resume at 400 mg daily
Dasatinib CP, 100 mg daily ANC o0.5 × 109/l and/or
platelets o50 ×109/l
(1) Stop dasatinib until ANC 41.0 × 109/l and platelets450× 109/l4resume the
original starting dose
(2) If platelets o25× 109/l and/or recurrence of ANC o0.5 × 109/l, repeat step 1
and resume dasatinib at a reduced dose of 80 mg once daily for the second
episode. For third episode, further reduce to 50 mg daily (newly diagnosed
patients) or discontinue dasatinib (for patients resistant or intolerant to prior
therapy including imatinib)
Dasatinib AP, BP and Ph+ ALL,
140 mg daily
ANC o0.5 × 109/l and/or
platelets o10 ×109/l
(1) Check if neutropenia is related to leukaemia (marrow aspiration or biopsy)
(2) If UNRELATED to leukaemia, stop dasatinib until ANC ⩾ 1.0 × 109/l and platelets
⩾ 20× 109/l and resume the original dose
(3) If recurrence of cytopenia, repeat step 1 and resume dasatinib at a reduced
dose of 100 mg once daily (second episode) or 80 mg once daily (third episode)
(4) If cytopenia is related to leukaemia, consider dose escalation to 180 mg once daily
Bosutinib CP, AP, BP CML, 500 mg
daily
ANC o1.0 × 109/l and/or
platelets o50 ×109/l
(1) Withhold bosutinib until ANC ⩾ 1.0 × 109/l and platelets ⩾ 50× 109/l
(2) Resume treatment with bosutinib at the same dose if recovery occurs within
2 weeks. If blood counts remain low for42 weeks, reduce dose by 100 mg and
resume treatment
(3) If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and
resume treatment
Doses o300 mg/day have not been evaluated
Ponatinib CML, CP, AP and BP or
Ph+ ALL, 45 mg daily
ANC o1.0 × 109/l and/or
platelets o50 ×109/l
(1) First episode: stop ponatinib until ANC 41.5 × 109/l and platelets 475× 109/l
and resume at 45 mg daily
(2) Second episode: stop ponatinib until ANC41.5 ×109/l and platelets475×109/l
and resume at 30 mg daily
(3) Third episode: stop ponatinib until ANC 41.5 ×109/l and platelets 475×109/l
and resume at 15 mg daily
Abbreviations: ALL, acute lymphoblastic leukaemia; ANC, absolute neutrophil count; AP, accelerated phase; BP, blastic phase; CML, chronic myeloid leukaemia;
CP, chronic phase.
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Table 9. Incidence of gastrointestinal AEs and pancreatitis
Drug/Side effects in % Nausea Abdominal pain Vomiting Dyspepsia Diarrhoea Constipation Pancreatitis
Imatinib
Trial: O´Brien et al.1
Design: randomized trial, newly diagnosed CML CP patients
Planned dose: 400 mg daily. N= 551
All grades 43.7 27.7 16.9 16.2 32.8 8.5 NR
Grades 3 and 4 0.7 2.4 1.5 0 1.8 0.7 NR
Trial: Druker et al.174
Design: follow-up of IRIS
Planned dose: 400 mg daily. N= 382
All grades 50 37 NR NR 45 NR NR
Trial: Deininger et al.175
Design: randomized trial, newly diagnosed CML CP patients
Planned doses: 400 vs 800 mg daily. N= 145
All grades, 400 vs 800 mg 50 vs 58 NR 15 vs 28 Anorexia:
15 vs 22
39 vs 56 NR NR
Grades 3 and 4, 400 mg vs 800 mg 3 vs 3 NR 1 vs 0 0 vs 0 1 vs 6 NR NR
Nilotinib
Trial: Kantarjian et al.105
Design: single-arm phase 2 trial, imatinib resistant or intolerant CP CML patients
Planned dose: 400 mg twice daily. N= 321
All grades 25 NR 13 NR 12 13 47a
Grades 3 and 4 o1 NR o1 NR 2 o1 18a
Trial: Saglio et al.2
Design: randomized trial, 3 arms, newly diagnosed CML CP patients, imatinib vs nilotinib in two dose regimens
Planned doses: 300 mg (N= 282) or 400 mg twice daily (N= 281)
All grades, 300 mg vs 400 mg 11 vs 19 NR 5 vs 9 NR 8 vs 6 NR 24 vs 29a
15 vs 18b
Grades 3 and 4, 300 mg vs 400 mg o1 vs 1 NR 0 vs 1 NR 1 vs 0 NR 6 vs 6a
o1 vs 1b
Dasatinib
Trial: Kantarjian et al.4
Design: randomized trial, newly diagnosed CML CP patients, imatinib vs dasatinib
Planned dose: 100 mg once daily (N= 258)
All grades 8 NR 5 NR 17 NR NR
Grades 3 and 4 0 NR 0 NR o1 NR NR
Trial: Shah et al.106
Design: randomized trial, CML CP patients with resistance, suboptimal response or intolerance to imatinib
Planned doses: 100 mg once daily vs 50 mg twice daily vs 140 mg once daily vs 70 mg twice daily (N= 670)
All grades, 100 mg once daily vs 50 mg twice
daily vs 140 mg once daily vs 70 mg twice daily
18 vs 20 vs
24 vs 29
12 vs 12 vs 13 vs 10 7 vs 10 vs
10 vs 13
5 vs 3 vs
10 vs 7
25 vs 31
vs 29 vs
27
9 vs 10 vs 3
vs 2
NR
Grades 3 and 4, 100 mg once daily vs 50 mg
twice daily vs 140 mg once daily vs 70 mg
twice daily
1 vs 1 vs 1 vs
1
1 vs 0 vs 1 vs 1 1 vs 1 vs 1
vs 0
0 vs 0 vs 0
vs 0
1 vs 2 vs
4 vs 4
1 vs 0 vs 0
vs 0
NR
Bosutinib
Trial: Khoury et al.107
Design: phase 2 study in CML CP patients after imatinib and dasatinib and/or nilotinib failure
Planned doses: 500 mg once daily (N= 118)
All grades 43 15 (upper abdominal
pain 13%)
32 NR 81 NR 24c
Grades 3 and 4 0 0 1 NR 8 NR 7c
Trial: Cortes et al.22
Design: randomized trial, newly diagnosed CML CP patients, imatinib vs bosutinib
Planned doses: 500 mg once daily (N= 248)
All grades 31 11 (+ upper
abdominal pain 12%)
32 NR 68 NR 38a
Grades 3 and 4 1 1 (upper abdominal
pain 0%)
3 NR 11 NR 9a
ELN recommendations for adverse events in CML
JL Steegmann et al
1660
Leukemia (2016) 1648 – 1671 © 2016 Macmillan Publishers Limited
may be considered, though the chance of similar problems on an
alternative TKI is high.
Management in advanced phase: In patients with advanced
phase disease, the management of severe myelosuppression
(Table 8) follows the general concept of keeping a higher dose
intensity than for chronic phase. In the face of a persistent
cytopenia, a bone marrow examination may be useful in order to
differentiate persistence of leukaemia from hypocellularity,
especially if the patient is treated with imatinib or dasatinib. It is
unclear whether continuing TKI treatment, despite myelosuppres-
sion, improves the response rate or simply results in greater
morbidity (infectious and/or bleeding complications). Advanced
phase CML poses highly variable haematological and clinical
situations, and therefore the TKI dose management should be
optimised based on the individual characteristics of each case.
Use of growth factors: The incidence of severe infections during
the course of TKI treatment is low. Prolonged therapy-induced
myelosuppression may, however, increase the risk of severe
infection. G-CSF and erythropoietic agents can be used transiently
to facilitate neutrophil or haemoglobin recovery. The concomitant
use of G-CSF171,172 or erythropoietic agents170 with TKIs is effective
and does not appear to be associated with lower response or TKI
failure.
Febrile neutropenia: If the patient is in chronic phase and
receiving TKI as ﬁrst line, in the case of grade 3, withhold therapy,
treat infection appropriately, and resume at a lower dose when
the grade resolves to o3. The same strategy is recommended for
grade 4, except that G-CSF should be considered together with a
switch to another TKI when the grade resolves to o3. If the
patient is in second line or in advanced phase, and switching
options to another TKI are limited, then a stepwise lowering of the
dose is warranted.
Prevention and management of bleeding: Dasatinib,164,166,167
and to a lesser extent imatinib167 and ponatinib168 induce platelet
dysfunction. Antiplatelet therapy must be used carefully in the
presence of TKIs, especially when dasatinib is used as second
line,19 or with ponatinib.165 In addition, adjustment of warfarin or
acenocoumarol is recommended, because imatinib may increase
their serum levels.
Cross-intolerance: Nilotinib, at a dose of 400 mg twice daily121
and dasatinib at various doses have been used as second-line
treatment for haematological intolerance to imatinib,173 which
represents a combination of toxicity and of resistance to imatinib
itself. Recurring grade 3–4 cytopenias after switching seem to be
more common with dasatinib (86%) than with nilotinib (55%), but
discontinuation due to recurrence of haematological toxicity is
similar (16% vs 23%).
Gastrointestinal problems
Incidence and severity. Gastrointestinal side effects are frequently
reported toxicities of TKIs. Table 9 summarises published data
from large trials.1,2,105,174,175 For imatinib and nilotinib, the most
frequent side effects are nausea, diarrhoea, abdominal pain and
vomiting; dyspepsia and constipation are less frequent. In the vast
majority of patients, the side effects are of grades 1 and 2 only.
The gastrointestinal tolerability of dasatinib is generally good.4
Diarrhoea was the reason for dose interruption in 1–3% of
patients, and diarrhoea or dyspepsia each were the reasons for
dose reductions in 0–2% of patients.106
Gastrointestinal problems are similar with bosutinib, with the
exception of diarrhoea, which is more frequent and annoying. It
starts typically in the ﬁrst 4 weeks, with a median of 1.5–3 days,
and the median duration is 2–7 days. Grades 3–4 are seen in
8–11%. Of those who experienced diarrhoea, 21% and 8% of
patients required dose interruptions and reductions, respectively.
Per protocol, it was recommended that at the ﬁrst sign of
diarrhoea, medications such as diphenoxylate/atropine or loper-
amide should be used as needed, which effectively controlled
diarrhoea in most instances; such concomitant medication was
required in 67% of patients. Discontinuation because of diarrhoea
was rare.22,107 For ponatinib, gastrointestinal toxicity is usually not
a major issue; some patients report nausea, abdominal pain or
constipation.23,135
Kinetics and prevention. Most gastrointestinal problems occur
during the ﬁrst month of therapy, and preventive measures are
therefore most appropriate at this time. However, one must take
into account that, for example, bosutinib-related diarrhoea may
appear as late as 18 months after starting TKI.22 In patients treated
with imatinib for least for 3 years, only 72% and 57% of patients
were free of nausea and diarrhoea respectively,176 even though
these cluster in the ﬁrst year.22,35
Few data are available about preventive measures. To avoid or
mitigate nausea and vomiting, imatinib should be taken with food
and administered with the largest meal of the day. Another
management strategy involves splitting the dose and taking them
with separate meals. Alternatively, some patients prefer to take
the TKI at bedtime to avoid the burden of nausea during
waking hours.
Table 9. (Continued )
Drug/Side effects in % Nausea Abdominal pain Vomiting Dyspepsia Diarrhoea Constipation Pancreatitis
Ponatinib
Trial: Cortes et al.135
Design: phase 2 trial in Ph+ leukaemias (six different cohorts of CML and Ph+ ALL)
Planned doses: 45 mg once daily (N= 449)
All grades 3–19 in
different
cohorts
10–27 in different
cohorts
NR NR NR 5–20 in
different
cohorts
0–8 in
different
cohortsd
Grades 3 and 4 0 to o1 in
different
cohorts
2–7 in different
cohorts
NR NR NR 0–3 in
different
cohorts
0–6 in
different
cohortsd
Abbreviations: ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukaemia; CP, chronic phase; NR, not reported. Side effects, grading according to
NCI-CTC (Common Terminology Criteria for Adverse Events of the National Cancer Institute). aReported as elevated lipase. bReported as elevated amylase.
cReported as elevated lipase, and reported to be present in 6% of cases at baseline. dIncreased lipase of any grade reported separately in 9–21% patients in
different cohorts (21% in the largest cohort, CP CML, n= 270), and of grade 3–4 in 6–13% patients in different cohorts (10% in the largest cohort, CP CML, n= 270).
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Management: Mild and transient nausea, vomiting and diar-
rhoea do not require therapy other than symptomatic relief and
diet modiﬁcation, unless they interfere with quality of life. For
more severe cases, antiemetic and antidiarrhoeal medication
should be utilised, and attention must be paid to drug interactions
and hydration,177 and the general rules of toxicity management
should be applied. In the case of bosutinib, we recommend to
start with medications such as diphenoxylate/atropine or loper-
amide at the ﬁrst sign of diarrhoea.74 In the case of abdominal
pain, gastric and pancreatic problems must be ruled out. Proton-
pump inhibitors may be helpful, though their dosing should be
separated from dasatinib intake by 12 h.
Gastrointestinal bleeding: Gastrointestinal bleeding may be
more frequent in patients receiving dasatinib especially in second
line, with a frequency of 17% across all phases. Basic coagulation
studies were normal in 97% of patients. Sixty-three percent of
episodes occurred with platelet counts ⩽ 100× 109/l, and throm-
bocytopenia and advanced phase CML were independent risk
factors for bleeding.164 In chronic phase, in second line it occurred
in 2–5% of patients.106 In ﬁrst line, it has not been reported.178
Management should include investigations to ﬁnd the source of
bleeding, coagulation studies and interruption of the drug.
Switching TKI may be necessary especially in the case of dasatinib,
and probably of ponatinib.
Pancreatic problems
Incidence and severity. It is important to note that lipase or
amylase elevations may occur in the absence of evidence of
pancreatitis,179 and with all TKIs, although clinical awareness
should be high in patients treated with nilotinib and ponatinib. In
patients treated with nilotinib, lipase elevations have been
reported with a frequency of 29–47%, with grade 3–4 elevations
ranging between 6 and 18%, being higher in second line.
Pancreatitis has been rare, between 0.9%180 and 2%.2 In patients
treated with ponatinib in chronic phase, in second line or further,
lipase elevations were recorded in 20% of the patients (10% grade
3–4).23 Pancreatitis occurred in 7%, tended to appear early
(median time to onset of 14 days, 69% of cases occurred in the
ﬁrst month and 17% in the second month) and was reversible
(most cases resolved within 1 week). All patients with pancreatitis
resumed treatment with ponatinib, and three patients had
recurrent events (multiple events occurred in one patient). Only
one patient discontinued treatment because of pancreatitis.23
Management. Suspicion of pancreatitis is always a call for action,
and the advice of an appropriate gastroenterologist or surgeon may
be needed. If the patient is asymptomatic but with grade 3 lipase/
amylase elevation, withholding therapy and resuming at a lower
dose when the grade is o2 is the recommended approach. If full
recovery takes more than 4 weeks, therapy should be stopped. In
the case of symptoms, CT scan is recommended, and if it is positive
or the pancreatitis is grade 3, stopping nilotinib is mandatory,
whereas in the case of ponatinib (which is normally used when other
options are ineffective or contraindicated), withholding therapy and
resuming at a lower dose could be reasonable. Stopping therapy
is mandatory for pancreatitis grade 4, irrespective of whether the
concurrent TKI is thought to be causal.
Cutaneous problems
Incidence and severity
Imatinib: Skin AEs are common with imatinib and occur in
7–89% of patients across different series.181–186 In particular, in a
large series of 532 chronic phase patients the frequency was 32%,
described mostly as skin eruption.187 In advanced phase patients,
skin AEs occurred in 23% of cases.188 They appear predominantly
during the ﬁrst 3–4 weeks of treatment181 The severity is dose-
dependent with a rate of 7% of skin events in patients receiving
standard dose of imatinib (400 mg daily) compared with a variable
rate between 20 and 88% in patients treated with higher doses of
imatinib.181–185 The manifestations are extremely heterogeneous.
Most common manifestations include peripheral oedema, macu-
lopapular erythematous rash, papulosquamous eruptions and
pigmentary changes. Most rashes are easily manageable and self-
limiting.30 Hypopigmentation,189,190 which can be generalised or
patchy,191 may include greying of hair192 and is reversible
after discontinuation.193 Less-common manifestations are skin
fragility,194 dermatoﬁbromas195 and exacerbations of porphyria
cutanea tarda.196 Photosensitivity and neutrophilic dermatosis are
rare.186
Nilotinib: Although ﬂuid retention is seen with nilotinib treat-
ment, with a frequency of 17% in ﬁrst line in the ﬁrst 3 years,3,197
periorbital oedema is relatively uncommon, and oedema is less
apparent than with imatinib. A rash is roughly twice as common
with nilotinib as with imatinib in ﬁrst line,3,197 and its incidence
appears to be lower in second line.180 It is usually localised to the
trunk, face and scalp.198 Other side effects are pruritus (24%), dry
skin (10%) and rarely alopecia (6%).149,180,199 Sweet’s syndrome is
uncommon.200
Dasatinib: The frequency of peripheral ﬂuid retention is similar in
ﬁrst line (19%)201,202 and second line (26%)150 and lower than with
imatinib.201,202 A rash has been described in 11% in ﬁrst line,201,202
in 18% by 36 months150,203 and 33% by 6 years.19 A recent meta-
analysis has shown that the incidence of rash is lower with
dasatinib than with nilotinib.198
Bosutinib: Fluid retention has been described in 15% of the
patients in second line21 and in less than 10% in ﬁrst line.22,29 A
rash has been described in 43% (6% of grade 3–4 severity), when
used in patients resistant/intolerant to imatinib in second line.21 In
ﬁrst-line use, 20% of patients experienced a skin rash in the ﬁrst
year, but only 1% as grade 3–4.22,29
Ponatinib: Overall, the incidence of a rash was 34% in the PACE
trial and 32% in the phase I trial, being of grade 3–4 severity in 3–
4%.23,135 It has been reported as an early event, without evidence
of tardive side effects.
Conditions that facilitate skin adverse events: Most cutaneous
AEs are probably due to a direct drug effect. Several conditions
may contribute to the occurrence of skin adverse events that
require particular attention. Cardiovascular diseases, older age and
higher doses predispose to oedema. Rash is more frequent with
higher doses, drugs that have CYP3A4 interactions, dehydration
and salty food, sunburn and skin contusions.181,183,185
Management. The severity of cutaneous side effects is dose-
related, but most of them are mild to moderate and self-limiting. A
dermatologist may be required to direct treatment. Mild to
moderate AEs can be managed with topical therapies (lotions or
glucocorticoids), systemic therapies with antihistamines or short
courses of systemic steroids. Severe cases always require
interruption or temporary reduction of TKI. Rare cases of very
severe skin reactions require the permanent withdrawal of the
causative TKI.181,185,204–206
In case of temporary discontinuation, weekly monitoring and
prednisone (1 mg/kg daily) should be started with gradual
reintroduction of the TKI at a reduced dose. Often, the skin rash
does not recur when the same TKI is restarted, particularly with a
reduced dose.207 If, in spite of all the supportive measures, the skin
reaction does not resolve, the patient should be deemed
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intolerant to that particular TKI, and a switch to other TKIs should
be evaluated. Patients who develop a rash on imatinib do not
appear to experience a recurrence on dasatinib or other TKIs.173 If
no other options are available to control the CML, treatment with
the offending TKI may be continued with concomitant oral steroid,
despite the persistence of skin reaction.
Immunological alterations and infections
Incidence and severity. All TKIs have a potential immunosuppres-
sive effect (reviewed in refs 15,144,146,147). In vitro studies have
shown that imatinib, dasatinib and nilotinib have inhibitory effects
on T-cell proliferation and activation.208 The in vitro effects of
dasatinib have been found to be more profound, probably due to
more potent off-target inhibition and a broader kinase target
spectrum.209 With imatinib, infection by opportunistic agents and
viruses does not appear to be a major problem.210 In a series of
771 patients across all disease phases treated with imatinib, the
incidence was low (2%), and only 1 with varicella.211 Hepatitis B
reactivation has been described during imatinib treatment.212
Reactivation of pulmonary tuberculosis while on imatinib has
been reported.213 Two cases of granulomatous lymphadenitis
have also been described.214 However, one out of four elderly
patients treated with imatinib developed infections.215
With regard to 2G TKIs, for chronic phase recipients of second-
line nilotinib, infection was one of the most common AEs, but of
mild nature.216 Febrile neutropenia has been a common AE in
advanced phase patients treated in second line with nilotinib.217
Dasatinib at higher doses, in second line, has been associated with
an ~ 50% incidence of infections when used in BCR-ABL1 positive
acute leukaemia,218 or with previous ara-C or rapamycin,219 or
with other antineoplastic agents or glucocorticoids.218 Infections
have not been frequently associated with ponatinib in second or
later lines.23 In large phase II/III clinical studies with dasatinib,220
nilotinib197 or bosutinib74 in ﬁrst line, no signiﬁcantly increased
rates of infections have been reported in comparison with
imatinib.
Therefore, in spite of the immunosuppressive in vitro effects of
TKIs, the incidence of infections seems to be slightly augmented in
second line, advanced phases and elderly people. In ﬁrst line,
there is no signiﬁcant difference between imatinib and other TKIs,
although the incidence with dasatinib appears to be higher, also
at 100 mg once daily.4,5,87
Prevention and management. Attention is most needed in elderly
patients treated with imatinib,215 patients treated with dasatinib,
and in the presence of neutropenia (see above). Responses to
vaccination against inﬂuenza and pneumococcus are blunted in
TKI treated patients.221 Concomitant use of antiviral agents should
be recommended on TKI therapy for prevention of hepatitis B
virus reactivation.222 A watchful attitude is recommended in
patients with previous tuberculosis. In patients treated with
dasatinib, cytomegalovirus reactivation should be considered in
the presence of large granular lymphocytosis (LGL)223,224 or
colitis.225,226
Dasatinib and lymphocytosis. In dasatinib-treated CML and
Philadelphia chromosome positive acute lymphoblastic leukaemia
(Ph+ ALL) patients, an oscillating LGL has been observed. This
phenomenon has not been described with other TKIs, and its
incidence in second line is roughly 50%.227,228 The time of
appearance is typically at 4–5 months on therapy.227,228 This LGL is
caused for the most part by rapid mobilisation of cytotoxic CD8+
T cells and NK cells into the blood 1–2 h after intake of
dasatinib.229 The actual incidence of LGL in ﬁrst-line dasatinib
therapy is not known, although in the DASISION trial the
cumulative 2-year probability of a lymphocytosis was 26%
(vs 6% with imatinib).230 Lymphocytosis (total or LGL) seems to
be more frequent in patients with pleural effusions,230,231 colitis232
or better responses.227,231,233 In some cases, cytomegalovirus
reactivation has been associated with LGL.223,225
Musculoskeletal effects
Incidence and severity. Under this heading, we have included
such AEs as muscle and bone pain, arthralgia, myalgia and muscle
cramps. In the IRIS trial, whereas muscle pain, myalgia and
arthralgia were less frequent with imatinib than with interferon
plus ara-C, it was the opposite with muscle cramps (38% vs 11%).1
When imatinib was compared with dasatinib in ﬁrst-line therapy,
the incidence of myalgia was more frequent with imatinib
(1st year: 34.5% vs 19.8%).178 However the incidence of myalgia
appears roughly the same with nilotinib and imatinib, whereas
muscle cramps are more frequent with imatinib (24% vs 7%).2
Grade 3–4 muscle pain is reported in o2% of cases. However,
muscle cramps are disturbing, and they interfere with quality of
life.234 Their pathogenesis is unknown, although they have been
linked with low adjusted calcium levels.235
Prevention and treatment. Other than symptomatic relief, there is
no deﬁnitive treatment. Serum electrolyte levels should be
monitored and corrected, if necessary. Some patients ﬁnd relief
with the use of beverages containing quinine.
Ocular adverse events
Incidence and severity. A spectrum of ophthalmological side
effects has been reported on TKI therapy, predominantly minor
and self-limiting. Despite shared inhibition of signalling pathways
between the TKIs, the bulk of ocular side effects lie with imatinib.
Periorbital oedema is the most frequent ocular side-effect
associated with imatinib236 and can occur in up to 70% of treated
patients,237 probably through the inhibition of platelet-derived
growth factor receptor.238 Epiphora (excessive watering of the
eye) occurs in roughly 20% of patients,238 as a result of
conjunctival chemosis.236 Conjunctival haemorrhage has been
reported in 11% of patients, in the absence of cytopenias or
bleeding diathesis.239 Rare and reversible imatinib-induced optic
disc oedema and optic nerve dysfunction, and neuritis have been
described.240,241
With nilotinib, there is a paucity of published data. Ocular side
effects (⩾1/100 too1/10) associated with nilotinib include
periorbital oedema, eye pruritus and dryness including xer-
ophthalmia. Uncommonly, visual impairment, conjunctival hae-
morrhage and eye irritation occur. Papilloedema and optic neuritis
have not been reported.242 The literature on dasatinib-induced
ophthalmological toxicity is absent, but common documented
side effects include eye dryness, visual disturbance and reduction
in acuity. Uncommonly (⩾1/1000 to o1/100), photophobia and
excess lacrimation have been reported.243 No ocular side effects
have been reported with bosutinib therapy.244 Although there are
no published references to ponatinib-related ophthalmological
AEs, common reported eye disorders have included blurring of
vision, eye dryness and periorbital oedema. Reports of ocular
arterial thrombosis/occlusion on ponatinib therapy are uncom-
mon, as are retinal vein thrombosis or occlusion.245
Prevention and management. Loss of visual acuity should prompt
examination for imatinib-induced optic disc oedema,240 or optic
nerve dysfunction and neuritis,241 rare but serious conditions that
are reversible after TKI discontinuation or additional systemic
steroid therapy.240,241
Diuretic therapy has limited beneﬁt in periorbital oedema, and
its management includes dose modiﬁcation and ultimately
changing to an alternative TKI as necessary.236 Surgical debulking
has been described but is rarely appropriate.246 Epiphora may
respond to diuretics and steroids.236 Conjunctival haemorrhage is
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normally self-limiting, and disturbing cases sometimes respond to
topical steroids.239
Gynaecologic adverse events
Incidence and severity. In non-clinical animal studies, fertility does
not appear to be inﬂuenced by imatinib or nilotinib.242,247
However, formal clinical studies examining fertility and gameto-
genesis have not been undertaken. On the basis of non-clinical
ﬁndings, bosutinib has the potential to impair reproductive
function and fertility in humans. The effect of dasatinib and
ponatinib on fertility is as yet unknown.242–245,247 During imatinib
therapy, menorrhagia and irregular menstrual cycle are reported
as uncommon, but in practice are often under-reported; therefore
their true incidence is probably higher. More unusual side effects
include haemorrhagic corpus luteum/haemorrhagic ovarian cyst.
Dasatinib has also been associated infrequently with irregular
menstruation, but no effects on the menstrual cycle appear to
have been described with nilotinib and bosutinib.242 Limited
bleeding episodes on ponatinib have been noted and menor-
rhagia has not been described in the absence of other
haemostatic challenges.165
Prevention and management. The most important advice to
women of childbearing potential receiving any of the TKIs is to use
effective contraception during all TKI treatment due to documen-
ted teratogenicity, and to avoid breast feeding.248
Neurological adverse events
Incidence and severity. Headache is a very common neurological
AE associated with the use of all TKIs. Caution is required with
respect to a causal relationship between headache and TKI usage,
given the high frequency of headache in the general population and
the wide variation of observed frequencies across different clinical
trials. As an example, in newly diagnosed chronic phase patients
treated with imatinib at 400 mg daily, headache was reported in
31%1 23%2 10%178 and 8%.22 In newly diagnosed chronic phase
patients treated with nilotinib twice daily, dasatinib at 100 mg daily
or bosutinib at 500 mg daily, headache was observed in 39%,2
12%,22 and 10%178 of the cases, respectively. With ponatinib 45 mg
daily in second or later lines, headache was reported in 23%
of chronic phase patients but few cases were considered as drug-
related.23 Unfortunately, descriptive features of headache such as
episodic or chronic nature, duration and type are lacking.
Other TKI AEs affecting the nervous system are less frequent
and must be distinguished from other causes of neurological
disorders (including those induced by other drugs). Peripheral
neuropathy has been described during treatment with all TKIs and
is considered as uncommon (frequency ⩾ 1/1000 to o1/100) to
common (frequency ⩾ 1/100 to o1/10).152,158,249–253 Establish-
ment of a causal relationship between peripheral neuropathy and
the use of TKIs is limited to a few case reports in patients treated
with imatinib, as well as description of clinical features.254,255
Peripheral neuropathy is an important diagnosis as it affects
quality of life and can lead to signiﬁcant disability. In addition,
dose decrease or TKI discontinuation may lead to signiﬁcant
improvement.254,255 Most of the neuropathies diagnosed in CML
patients could be ascribed to concomitant or previous ailments
(diabetes, interferon-associated autoimmune phenomena and so
on). Memory impairment may occur in patients treated with
imatinib, dasatinib and nilotinib.158,249–251 Its exact frequency is
difﬁcult to estimate based on the available data. Whether memory
impairment may also arise in bosutinib- or ponatinib-treated
patients is unknown.
Other rare neurologic complications such as cranial nerve palsy,
optic neuritis and optic disc oedema240,241,255 may be associated
with the use of imatinib or dasatinib and their frequency cannot
be estimated from the available data. Cerebral oedema has been
reported in an isolated case report in an imatinib-treated
patient.256 Cerebral ischaemic events associated with the use of
ponatinib or nilotinib are discussed in the vascular section.
Intracranial bleeding is restricted to patients with thrombocyto-
penia and advanced phase CML.
Prevention and management. Headache, which is quite common
in the general population, is a common AE in TKI recipients.
Hypertension must be ruled out, especially in the case of
ponatinib. In the case of peripheral neuropathy, most cases have
other causes than TKI treatment. If TKI seems to be causal, dose
decrease or TKI discontinuation may lead to signiﬁcant
improvement.254,255
Renal adverse events
Incidence and severity. Initially, renal failure on account of
imatinib was reported as a rare event, shown to occur in o1%
patients in the dose-escalating studies of chronic phase and blast
crisis CML.257,258 Similarly, the Novartis Oncology Medical informa-
tion website (www.oncologymedicalservices.com) reported renal
function abnormalities in 1.6% of 1234 CML patients, and there
were no reports of renal failure among the 553 newly diagnosed
CML patients treated with imatinib in the IRIS trial, with up to 6
years of follow-up.
It is now clear that imatinib therapy can rarely be associated
with potentially irreversible acute renal injury, and long-term
treatment may cause a clinically relevant decrease in the
estimated glomerular ﬁltration rate. In 105 patients receiving
imatinib after prior interferon, 7% developed acute kidney injury,
the mean decrease of glomerular ﬁltration rate was 2.77 ml/min
per 1.73 m2 per year and 12% of patients developed chronic
renal failure.259 In other cases, renal failure linked to imatinib is
often reversible,260,261 although haemodialysis is sometimes
needed.262 Thrombotic thrombocytopenic purpura,263 acute
tubular necrosis,262 tubular vacuolisation264 and partial Fanconi
syndrome265 have all been reported following imatinib therapy.
Renal failure was not described in the dasatinib phase I–III
trials.83,84,266,267 However, renal failure has been reported with
dasatinib administration,268 and switching to nilotinib in blast
crisis has reversed acute kidney injury with maintenance of
stable renal function.81,269,270 Rarely dasatinib has been reported
to induce thrombotic thrombocytopenic purpura/haemolytic
uraemic syndrome either through an auto-immune mechanism
or by direct endothelial toxicity/acute tubular necrosis,270 salvage-
able by renal transplantation.269,271
None of the nilotinib-treated patients in the phase I and II
studies for CML or Ph+ ALL developed renal failure, although
tumour lysis syndrome remains a possibility.272 Nilotinib has been
reported to be beneﬁcial for renal dysfunction273 through the
dissipation of ﬁbrosis in chronic kidney disease. Increases in serum
creatinine and renal failure (o5%) have been observed with
bosutinib.244
Prevention and management. In the ﬁrst few days of treatment,
attention to tumour lysis syndrome is mandatory with all TKIs. In
the chronic setting, monitoring serum creatinine is needed in
patients treated with imatinib, and less stringently, with dasatinib
and bosutinib. There is no need in patients treated with nilotinib,
and it is uncertain with ponatinib. In renal insufﬁciency (ranging
from renal dysfunction to dialysis) a maximum imatinib starting
dose of 400 mg is recommended. No clinical studies have been
conducted with dasatinib, nilotinib or ponatinib in patients with
decreased renal function (43 times the upper limit of the normal
range), but the minimal or absent renal clearance of these two
drugs makes dose adjustment unnecessary for renal insufﬁciency.
Dasatinib administration in renal impairment has not led to
worsening of renal function.274 Nilotinib can be safely
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administered in patients receiving haemodialysis.275 With bosuti-
nib caution is recommended due to observed increases in serum
creatinine and renal failure (o5%).244 Caution is recommended
when administering ponatinib to patients with an estimated
creatinine clearance of o50 ml/min, or end-stage renal
disease.245
CONCLUSIONS
In summary, and despite the reservations mentioned in the
introduction, a number of things have been learnt in the recent
past. First, the main objective of CML treatment is the
antileukaemic effect and thus the minimisation of disease-
related mortality. Suboptimal management of AEs must not
compromise this ﬁrst objective. Second, most patients will have
AEs,7 usually early after treatment initiation, mostly mild to
moderate in intensity, and which will resolve spontaneously or are
easily controlled by simple means. Third, reduction or interruption
of treatment must only be done if optimal management of the AE
cannot be anticipated or accomplished. Dose reduction or
interruption must be kept to a minimum, and frequent patient
monitoring may be helpful in this regard, in order to detect
resolution of the AE as early as possible. Fourth, strict attention
must be given to comorbidities and drug interactions, and new
events unrelated to TKI are inevitable during such a prolonged
(lifelong) treatment; these new events may modify the choice of
TKI. Fifth, some TKI-related AEs have emerged that were not
predicted or detected in earlier studies, maybe because of
suboptimal attention to or absence from the preclinical data.
Overall, imatinib has demonstrated a good long-term safety
proﬁle, though recent ﬁndings suggest underestimation of
symptom severity by physicians.276 Second and third generation
TKIs may have higher response rates, but have been associated
with unexpected lung and vascular problems, which could be
irreversible. We hope these recommendations will help to
minimise adverse events, and we believe that an optimal
management of them will be rewarded by better outcomes, and
better quality of life.
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